A Phase III Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Asklepion Pharmaceuticals, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT06989567
- Locations
- 🇺🇸
Children's National Hospital, Washington, District of Columbia, United States
🇺🇸University of Miami, Coral Gables, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects
- Conditions
- Ventricular Septal DefectAtrioventricular Septal DefectPrimum Atrial Septal Defect
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Asklepion Pharmaceuticals, LLC
- Target Recruit Count
- 97
- Registration Number
- NCT05253209
- Locations
- 🇺🇸
Children's of Alabama, Birmingham, Alabama, United States
🇺🇸Children's Hospital of Colorado, Aurora, Colorado, United States
🇺🇸Heart Center, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
L-citrulline Injection in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting With Vaso-Occlusive Crisis (VOC)
- Conditions
- Acute Vaso Occlusive Crisis (VOC)
- Interventions
- Other: D5 1/2NS
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Asklepion Pharmaceuticals, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT04852172
- Locations
- 🇺🇸
Children's National Hospital, Washington DC, District of Columbia, United States
🇺🇸The University of Mississippi Medical Center, Jackson, Mississippi, United States
Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19
- Conditions
- Acute Hypoxemic Respiratory Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Asklepion Pharmaceuticals, LLC
- Target Recruit Count
- 65
- Registration Number
- NCT04570384
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Asklepion Pharmaceuticals, LLC
- Target Recruit Count
- 189
- Registration Number
- NCT02891837
- Locations
- 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol
- Conditions
- Atrial Septal DefectVentricular Septal DefectAtrioventricular Septal Defect
- Interventions
- First Posted Date
- 2010-05-11
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Asklepion Pharmaceuticals, LLC
- Target Recruit Count
- 22
- Registration Number
- NCT01120964
- Locations
- 🇺🇸
Washington University Children's Hospital, Saint Louis, Missouri, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery
- Conditions
- Heart Defects, CongenitalHypertension, Pulmonary
- Interventions
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- Asklepion Pharmaceuticals, LLC
- Target Recruit Count
- 77
- Registration Number
- NCT00335244
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States